News Room

All Press Releases In The News Blogs
30 Mar 2023
Press Release
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases 
Granular Therapeutics Limited
16 Mar 2023
Press Release
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
03 Oct 2022
Press Release
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody 
Villaris
04 Aug 2022
Press Release
Medicxi portfolio company MiroBio to be acquired by Gilead Sciences for approximately $405 million 
03 May 2022
Press Release
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) 
Phathom Pharmaceuticals
28 Nov 2022
Press Release
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease 
New Amsterdam
04 Oct 2022
Press Release
Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants 
Rivus Pharmaceuticals, Inc
22 Aug 2022
Press Release
Backed by Medicxi, Novartis vets launch rare blood disorder biotech with fresh take on drug class used in cancers 
Vaderis Therapeutics AG
29 Jun 2022
Press Release
MiroBio Raises $97 Million Series B Financing to Develop Checkpoint Agonists for Treatment of Autoimmune Diseases 
09 Feb 2022
Press Release
Rivus Pharmaceuticals Announces Positive Data from Phase 2a Clinical Trial of Lead Candidate HU6, Demonstrating Fat Reduction and Weight Loss in High BMI Participants 
Rivus Pharmaceuticals, Inc
09 Feb 2022
Press Release
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD) 
Phathom Pharmaceuticals
08 Sep 2021
Press Release
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor 
Xenikos
27 Jul 2021
Press Release
Kurome Therapeutics Closes $15 Million Series A Financing to Develop Targeted Kinase Inhibitors for Treatment of Hematopoietic Cancers 
Kurome Therapeutics
20 Jul 2021
Press Release
Rivus Pharmaceuticals Launches with $35 Million Series A Financing to Develop Novel Treatments for Cardio-Metabolic Diseases 
Rivus Pharmaceuticals, Inc
28 May 2021
Press Release
Centessa Announces Pricing of Initial Public Offering 
Centessa - (NASDAQ: CNTA)
22 Apr 2021
Press Release
Monopteros Therapeutics Initiates Clinical Trial to Reprogram Regulatory T Cells in Solid Tumors 
22 Mar 2021
Press Release
Aura Biosciences Announces Oversubscribed $80 Million Financing 
Aura - (NASDAQ: AURA)
16 Feb 2021
Press Release
Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model 
19 Nov 2020
Press Release
SynOx Therapeutics raises €37M in Series A Financing 
25 Sep 2020
Press Release
PALLADIO COMPLETES $20 MILLION SERIES B FINANCING 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
22 Sep 2020
Press Release
Medicxi announces the closing of its first €200 million Secondary Fund, led by Pantheon with co-lead LGT Capital Partners
19 Aug 2020
Press Release
First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency 
Z Factor - Centessa Therapeutics (NASDAQ:CNTA)
15 May 2020
Blog
Operation Warp Speed – Moncef Slaoui’s mission to deliver a COVID-19 vaccine
by Francesco De Rubertis
17 Mar 2020
Press Release
Medicxi Bolsters and Expands Team with Senior Industry Leaders
07 Feb 2020
Press Release
What is Villaris Therapeutics and how will it help my vitiligo? 
Villaris
18 Dec 2019
Press Release
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial 
Xenikos
09 Dec 2019
Press Release
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting 
Xenikos
22 Oct 2019
Press Release
ApcinteX Starts Clinical Trial of Novel Haemophilia Drug 
ApcinteX - Centessa Therapeutics (NASDAQ:CNTA)
14 Oct 2019
Press Release
Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease 
Xenikos
18 Sep 2019
Press Release
Divide & Conquer, Developing New Class of Cancer Therapeutics to Disrupt Cell-to-Cell Communication, Emerges from Stealth as New Paper by Co-Founder is Published in Nature 
Divide and Conquer
19 Jul 2019
Press Release
Medicxi Closes a New €400m Fund (Medicxi III) to Power the Next Wave of Biopharma Entrepreneurs and Drug Hunters
08 Jul 2019
Press Release
Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH" 
Breakpoint Therapeutics
04 Jun 2019
Press Release
Yukin Therapeutics raises €3.3 million to develop new cancer treatments 
Yukin Therapeutics
15 May 2019
Press Release
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals 
Phathom Pharmaceuticals
13 May 2019
Press Release
Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs 
Minerva Neurosciences (NASDAQ: NERV)
02 Apr 2019
Press Release
Aura Biosciences Completes $40 Million Series D Financing 
Aura - (NASDAQ: AURA)
02 Apr 2019
Press Release
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol 
Molecular Partners (S​wiss​: MOLN.SW)
04 Feb 2019
In The News
Endpoints News
Medicxi bankrolls the launch of a pair of biotech twins focused on orexins for narcolepsy and more 
20 Dec 2018
Press Release
Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard® in acute graft-versus-host disease 
Xenikos
19 Dec 2018
Press Release
Molecular Partners and Amgen announce Strategic Collaboration in Immuno-Oncology 
Molecular Partners (S​wiss​: MOLN.SW)
18 Dec 2018
Press Release
Morphogen-IX raises £18.4M ($23.2M) in a Series B financing 
Morphogen-IX - Centessa Therapeutics (NASDAQ:CNTA)
12 Dec 2018
Press Release
GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
12 Dec 2018
Press Release
Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 
Synthorx - Synofi
28 Nov 2018
Press Release
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain 
Minerva Neurosciences (NASDAQ: NERV)
27 Nov 2018
Press Release
Morphogen-IX Announces MGX292 as Clinical Development Candidate 
Morphogen-IX - Centessa Therapeutics (NASDAQ:CNTA)
19 Nov 2018
Press Release
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers 
Minerva Neurosciences (NASDAQ: NERV)
31 Oct 2018
Press Release
Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products 
Egalet (NASDAQ:EGLT)
30 Oct 2018
Press Release
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET) 
ObsEva (NASDAQ: OBSV)
01 Oct 2018
Blog
Medicxi Expands the Partners Group
by Francesco De Rubertis
28 Sep 2018
Press Release
Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain 
ObsEva (NASDAQ: OBSV)
13 Sep 2018
Press Release
GenSight Biologics provides an update on the clinical and regulatory pathways for GS010 
Gensight (Euronext: SIGHT)
22 Aug 2018
Press Release
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF) 
Minerva Neurosciences (NASDAQ: NERV)
25 Jul 2018
Press Release
ObsEva Expands Executive Team Hiring a Chief Commercial Officer 
ObsEva (NASDAQ: OBSV)
19 Jul 2018
In The News
Endpoints News
Gilead brings Medicxi’s tiny Gadeta into the cell therapy fold, hunting a way to pick the lock on solid tumors 
19 Jul 2018
Press Release
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration 
Molecular Partners (S​wiss​: MOLN.SW)
19 Jul 2018
Press Release
Business Wire
Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors 
28 Jun 2018
In The News
Newswire
Morphogen-Ix Appoints CEO and Forms Global Scientific Advisory Board 
21 Jun 2018
Press Release
Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 
Molecular Partners (S​wiss​: MOLN.SW)
20 Jun 2018
In The News
L'Echo
'Investir dans les biotechs en Belgique? Une question de temps' 
12 Jun 2018
Press Release
GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON) 
Gensight (Euronext: SIGHT)
07 Jun 2018
Press Release
Egalet Appoints Industry Veteran John Varian to Board of Directors 
Egalet (NASDAQ:EGLT)
07 Jun 2018
Press Release
SutroVax Announces $85M Series C Financing led by TPG Growth 
Vaxcyte
29 May 2018
Press Release
Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
17 May 2018
Press Release
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia 
Minerva Neurosciences (NASDAQ: NERV)
15 May 2018
Press Release
Dutch Company Xenikos Secures USD 30 Million in Series B Financing 
Xenikos
08 May 2018
Press Release
Palladio Biosciences Receives FDA IND Clearance to Begin the ELiSA Study, a Phase 2 Clinical Trial with Lixivaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) 
Palladio Biosciences - Centessa Therapeutics (NASDAQ:CNTA)
30 Apr 2018
Press Release
Synthorx Announces $63 Million Series C Financing to Advance a Pipeline of Synthorin™ Cytokines 
Synthorx - Synofi
26 Apr 2018
Press Release
Further MP0250 clinical data and partner interest underline Molecular Partners’ continued progress of its proprietary oncology compounds 
Molecular Partners (S​wiss​: MOLN.SW)
17 Apr 2018
In The News
The Medicine Maker
Celebrating the World’s Top 100 Medicine Makers 
11 Apr 2018
Press Release
Molecular Partners and AstraZeneca announce collaboration on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated NSCLC 
Molecular Partners (S​wiss​: MOLN.SW)
22 Mar 2018
In The News
PR Newswire
Human Vaccines Project Appoints Dr. Moncef Slaoui as New Board Member 
20 Mar 2018
In The News
FierceBiotech
Medicxi founds biotech creation engine C21Med 
19 Mar 2018
Press Release
Medicxi unveils ‘The Foundation Institute’
19 Mar 2018
Blog
The Making of Medicxi: We have the Operating Partner
by Francesco De Rubertis
14 Mar 2018
In The News
BioWorld
BIO-Europe Spring Academic scientist injects dose of reality into microbiome debate 
09 Mar 2018
In The News
BioCentury
Reviving Lixivaptan 
26 Feb 2018
Press Release
ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF 
ObsEva (NASDAQ: OBSV)
20 Feb 2018
Press Release
Egalet Announces Issuance of New U.S. Patent for Guardian™ Technology 
Egalet (NASDAQ:EGLT)
20 Feb 2018
Press Release
GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology 
Gensight (Euronext: SIGHT)
19 Feb 2018
Press Release
Molecular Partners’ collaboration partner Allergan exercises the third option for a DARPin® product candidate in ophthalmology 
Molecular Partners (S​wiss​: MOLN.SW)
13 Feb 2018
Press Release
Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics Executive Michael Pellini, MD, to Board of Directors 
Sequenta  - Acquired by Adaptive Biotechnologies
08 Feb 2018
Press Release
Molecular Partners reports significant progress of pipeline and preliminary unaudited key financials for 2017 – Key value inflection points in 2018 
Molecular Partners (S​wiss​: MOLN.SW)
05 Feb 2018
Press Release
Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director 
Minerva Neurosciences (NASDAQ: NERV)
03 Feb 2018
In The News
Le Temps
Grande Interview - Francesco De Rubertis 
29 Jan 2018
Press Release
Egalet Announces ARYMO® ER Data Published in Current Medical Research and Opinion Journal 
Egalet (NASDAQ:EGLT)
25 Jan 2018
Press Release
GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update 
Gensight (Euronext: SIGHT)
25 Jan 2018
Press Release
GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing 
Gensight (Euronext: SIGHT)
24 Jan 2018
Press Release
Egalet to Co-Host Category 1 Focus Group 
Egalet (NASDAQ:EGLT)
23 Jan 2018
Press Release
Egalet's Partner OraPharma Begins Promotion of SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
10 Jan 2018
Press Release
GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa 
Gensight (Euronext: SIGHT)
08 Jan 2018
Press Release
Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma 
Molecular Partners (S​wiss​: MOLN.SW)
08 Jan 2018
In The News
Biotech Finances
Europe: Les Biotechs Early Stage Plus Attractives Que Jamais 
07 Jan 2018
In The News
Reuters
Celgene to buy Impact Biomedicines for up to $7 billion 
07 Jan 2018
Press Release
Celgene to acquire Impact Biomedicines, adding Fedratinib to its pipeline of novel therapies for hematologic malignancies 
Impact Biomedicines - (NYSE: BMY)
06 Jan 2018
Blog
Everyone Goes Home with a Balloon - Impact Biomedicines
by Kevin Johnson
04 Jan 2018
Press Release
Adaptive Biotechnologies Announces Partnership with Microsoft to Decode the Human Immune System to Improve the Diagnosis of Disease 
Sequenta  - Acquired by Adaptive Biotechnologies
03 Jan 2018
Press Release
Molecular Partners’ collaboration partner Allergan exercises options for two DARPin® product candidates 
Molecular Partners (S​wiss​: MOLN.SW)
03 Jan 2018
Press Release
Egalet Partners with OraPharma to Co-Promote SPRIX® Nasal Spray 
Egalet (NASDAQ:EGLT)
21 Dec 2017
Press Release
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder 
Minerva Neurosciences (NASDAQ: NERV)
15 Dec 2017
Press Release
Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain 
Egalet (NASDAQ:EGLT)